newsfilter
← Latest News
Business Wire·

Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates

Bexicaserin (LP352) Phase 1b/2a PACIFIC Study positive topline data in participants with Developmental and Epileptic Encephalopathies (DEEs) was reported in January Announcing an update to the primary efficacy